Economics of Health Technology Assessment

This is part one of two posts containing posters and presentations by members of the OHE team at ISPOR’s 21st Annual International Meeting held in Washington DC, 20-25th May 2016.

The blog provides links to slide sets and posters relating to the value footprint of oncology treatments, treating obstructive sleep apnoea and sources of motivation in health care organisations.

In June 2015 OHE’s Nancy Devlin gave a seminar at the Royal Statistical Society on the topic of patient-reported outcomes measures (PROMs) in health economics – providing an overview and highlighting key developments in the field.

OHE’s Adrian Towse will give a lecture at the Medical University of Vienna on relative effectiveness and the impact on drug development.

This mapping of priority-setting considers factors such as existence of HTA institutions and commitment to UHC (Brazil, Chile, Colombia, Mexico, Uruguay, Ghana, Kenya, Malawi, South Africa, Uganda, China, India, Indonesia, Myanmar, Philippines, Thailand and Vietnam).

Articles co-authored by Adrian Towse, Martina Garau, Donna Messner, and Penny Mohr exploring future expectations of drug relative effectiveness in Europe and comparative effectiveness in the USA just published online.

Hernandez-Villafuerte, K., Li, R., Towse, A. and Chalkidou, K.

Occasional Paper
April 2015

This mapping of priority-setting considers factors such as existence of HTA institutions and commitment to UHC (Brazil, Chile, Colombia, Mexico, Uruguay, Ghana, Kenya, Malawi, South Africa, Uganda, China, India, Indonesia, Myanmar, Philippines, Thailand and Vietnam).

Dr Steven Pearson has convened a US policy workgroup of payers, drug and device manufacturers, patients' groups, and clinician specialty societies to help develop a “value framework”.

Towse, A.

Occasional Paper
December 2014

This OHE Occasional Paper by Adrian Towse discusses Professor Bengt Jönsson’s observations in a 2011 publication about the role of relative effectiveness research (RE) in the European medicines market and how this could lead to improved efficiency in the development of medicines, the pricing and use of medicines, and of health systems.

The OHE presented the following posters at ISPOR 17th Annual European Congress in Amsterdam, The Netherlands.

Pages

Subscribe to RSS - Economics of Health Technology Assessment